A Breath of Fresh Air: Grade 4 Pneumonitis Secondary to HER2 Antibody-Drug Conjugate Therapy Treated with Plasma Exchange

被引：0
|
作者：
Teng, Christina [1 ,2 ]
Wei, Joe Q. [1 ,2 ,3 ]
Killen, Andrew [1 ]
Thirumaran, Aricia [2 ]
Lemech, Charlotte R. [1 ,2 ,4 ]
机构：
[1] Scientia Clin Res, Randwick, NSW, Australia
[2] Prince Wales Hosp, Randwick, NSW, Australia
[3] Univ Sydney, Camperdown, NSW, Australia
[4] Univ New South Wales, Kensington, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：60 / 61
页数：2
相关论文
共 50 条
  • [31] T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
    Nicoletti, Roberta
    Lopez, Salvatore
    Bellone, Stefania
    Cocco, Emiliano
    Schwab, Carlton L.
    Black, Jonathan D.
    Centritto, Floriana
    Zhu, Liancheng
    Bonazzoli, Elena
    Buza, Natalia
    Hui, Pei
    Mezzanzanica, Delia
    Canevari, Silvana
    Schwartz, Peter E.
    Rutherford, Thomas J.
    Santin, Alessandro D.
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (01) : 29 - 38
  • [32] T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
    Roberta Nicoletti
    Salvatore Lopez
    Stefania Bellone
    Emiliano Cocco
    Carlton L. Schwab
    Jonathan D. Black
    Floriana Centritto
    Liancheng Zhu
    Elena Bonazzoli
    Natalia Buza
    Pei Hui
    Delia Mezzanzanica
    Silvana Canevari
    Peter E. Schwartz
    Thomas J. Rutherford
    Alessandro D. Santin
    Clinical & Experimental Metastasis, 2015, 32 : 29 - 38
  • [33] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
    Zhang, Jian
    Du, Yiqun
    Meng, Yanchun
    Liu, Xiaojun
    Mu, Yuxin
    Liu, Yunpeng
    Shi, Yehui
    Wang, Jufeng
    Zang, Aimin
    Gu, Shanzhi
    Liu, Tianshu
    Zhou, Huan
    Guo, Hongqian
    Xiang, Silong
    Zhang, Xialu
    Wu, Suqiong
    Qi, Huanhuan
    Li, Mengke
    Hu, Xichun
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [34] Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer
    Pegram, M.
    Hamilton, E.
    Tan, A. R.
    Storniolo, A. M.
    Elgeioushi, N.
    Marshall, S.
    Abdullah, S.
    Patel, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Autophagy modulates intracellular dynamics of [fam-]trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)
    Abe, Manabu
    Nagata, Motoko
    Koyama, Kumiko
    Yasuda, Satoru
    Hirata, Tsuyoshi
    Kuwahara, Yusuke
    Inaki, Koichiro
    Kasanuki, Naomi
    Minami, Megumi
    Hagihara, Katsunobu
    Wakita, Kenichi
    Slosberg, Eric
    Murakami, Masato
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Preclinical development of DHES0815A: A HER2-directed antibody-drug conjugate comprised of a reduced potency PBD dimer linked to a domain I binding HER2 antibody
    Phillips, Gail Lewis
    Li, Guangmin
    Guo, Jun
    Yu, Shang-Fan
    Lee, Genee
    Zhang, Donglu
    Dragovich, Peter
    Pillow, Thomas
    Wei, Binqing
    Lee, M. Violet
    Saad, Ola
    Masih, Shab
    Leipold, Douglas
    Crocker, Lisa
    Schutten, Melissa
    CANCER RESEARCH, 2022, 82 (04)
  • [37] The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience
    Bjelobrk, Ivana Kolarov
    Radic, Jelena
    Trifunovic, Jasna
    Pesic, Jasna
    Vidovic, Vladimir
    Vranjkovic, Bojana
    Petrovic, Nemanja
    Visnjic, Bojana Andrejic
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (04) : 264 - 271
  • [38] MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment
    Ayako Nakashoji
    Atrayee Bhattacharya
    Hiroki Ozawa
    Naoki Haratake
    Keisuke Shigeta
    Atsushi Fushimi
    Nami Yamashita
    Akira Matsui
    Shoko Kure
    Tomoe Kameyama
    Makoto Takeuchi
    Kazumasa Fukuda
    Takamichi Yokoe
    Aiko Nagayama
    Tetsu Hayahsida
    Yuko Kitagawa
    Renyan Liu
    Antonio Giordano
    Rinath Jeselsohn
    Geoffrey I. Shapiro
    Donald Kufe
    npj Breast Cancer, 11 (1)
  • [39] ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
    Li, John Y.
    Perry, Samuel R.
    Muniz-Medina, Vanessa
    Wang, Xinzhong
    Wetzel, Leslie K.
    Rebelatto, Marlon C.
    Hinrichs, Mary Jane Masson
    Bezabeh, Binyam Z.
    Fleming, Ryan L.
    Dimasi, Nazzareno
    Feng, Hui
    Toader, Dorin
    Yuan, Andy Q.
    Xu, Lan
    Lin, Jia
    Gao, Changshou
    Wu, Herren
    Dixit, Rakesh
    Osbourn, Jane K.
    Coats, Steven R.
    CANCER CELL, 2016, 29 (01) : 117 - 129
  • [40] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
12345